DESTINY-PANTUMOUR04
Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study
- Adenocarcinoma (NOS)
- Anal Cancer
- Bladder Cancer
- Cervical Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gall Bladder Cancer
- Gastrointestinal Stromal Tumour
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- AstraZeneca
- Enrolment target
- 100
- Started
- 18 September 2025
- Main results due
- 30 March 2028
- Study sites
- 18
- Registry updated
- 25 September 2026
Can you take part?
- Ages 18 years to 130 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Adults aged ≥18 years 2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors); 3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label; 4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent; 5. Patients who are willing and able to provide a signed and dated informed consent. Exclusion Criteria: 1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies; 2. Prior T-DXd therapy; 3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd. 4. Patient is participating in a clinical trial at time of enrolment
What this study is about
In the sponsor’s own words, from the registry.
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Study sites(18)
Research Site
Birmingham, Alabama, United States
Recruiting
Research Site
Bullhead City, Arizona, United States
Recruiting
Research Site
Casa Grande, Arizona, United States
Recruiting
Research Site
San Diego, California, United States
Recruiting
Research Site
Boulder, Colorado, United States
Recruiting
Research Site
Coral Springs, Florida, United States
Recruiting
Research Site
St. Petersburg, Florida, United States
Recruiting
Research Site
West Palm Beach, Florida, United States
Recruiting
Research Site
Decatur, Illinois, United States
Recruiting
Research Site
Topeka, Kansas, United States
Recruiting
Research Site
Farmington, New Mexico, United States
Recruiting
Research Site
Durham, North Carolina, United States
Recruiting
Research Site
Wilson, North Carolina, United States
Recruiting
Research Site
Canton, Ohio, United States
Recruiting
Research Site
Maumee, Ohio, United States
Recruiting
Research Site
Philadelphia, Pennsylvania, United States
Recruiting
Research Site
Nashville, Tennessee, United States
Recruiting
Research Site
Dallas, Texas, United States
Recruiting
Showing 18 of 18 sites. 18 of the 18 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07124000. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me